Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Trubion CEO Peter Thompson Steps Down, Arch’s Gillis To Step Up Temporarily
|
Luke Timmerman |
11/16/09 |
Seattle
|
|
Trius Therapeutics Reveals Plans for IPO, SpectraScience Raises $4.3M, Sequenom Tightens its Belt, & More San Diego Life Sciences News
|
Denise Gellene |
11/12/09 |
San Diego
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
Good Things in Threes: Trius Therapeutics Files for IPO to Fund Phase 3 Clinical Trials, Marks San Diego’s Third IPO Filing
|
Bruce V. Bigelow |
11/09/09 |
San Diego
|
|
Concert Starts HIV Trial, Bags $12M From Glaxo to Help Challenge Gilead’s Once-Daily Pill
|
Luke Timmerman |
11/09/09 |
Boston
|
|
Isis CEO Vows that Cholesterol Drug, Partnered With Genzyme, Will be “Remarkable” Advance
|
Luke Timmerman |
10/21/09 |
San Diego
|
|
Flexion Pulls in $33M, Cubist Teams With Hydra, Charles River Makes Cuts, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/21/09 |
Boston
|
|
How to Tap Russia for Biomedical Breakthroughs: Lessons from Boston BioCom
|
Ryan McBride |
10/15/09 |
Boston
|
|
Bigtime Biotech Thinkers Steven Burrill and Gary Pisano Agree on Bright Future of Industry, Disagree on How to Build Value
|
Ryan McBride |
10/08/09 |
Boston
|
|
Neurocrine Cuts Office Costs
|
Denise Gellene |
10/01/09 |
San Diego
|
|
Swine Flu Could Benefit Some Biomedical Companies, Local Biotechs Are Looking Healthier, Arena Happy With Obesity Drug Results, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/24/09 |
San Diego
|
|
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs
|
Luke Timmerman |
09/18/09 |
San Diego
|
|
Brown U. and Johns Hopkins Researchers Form Sentient Bioscience to Improve Liver Cancer Treatment
|
Ryan McBride |
09/15/09 |
Boston
|
|
Ambit Biosciences, In Third Incarnation, Gears Up for Pivotal Study of Leukemia Drug
|
Luke Timmerman |
09/10/09 |
San Diego
|
|
OVP Company Does 14 Genomes
|
Luke Timmerman |
09/09/09 |
Seattle
|
|
Drugmaker Sepracor Accepts $2.6B Buyout Offer from Japan’s Dainippon
|
Ryan McBride |
09/03/09 |
Boston
|
|
Trubion Gets $20M Upfront in Leukemia Drug Partnership With Facet; Shares Boom
|
Luke Timmerman |
08/28/09 |
Seattle
|
|
Genocea, Attracting Merck and Wyeth Vaccine Gurus, Pushes New Immunizations to Clinic
|
Luke Timmerman |
08/26/09 |
Boston
|
|
Why Big Pharma Wants To Be Like Big Biotech
|
Stewart Lyman |
08/19/09 |
National
|
|
Rib-X Antibiotic Passes Clinical Trial, Hopes to Snag Partner
|
Luke Timmerman |
08/05/09 |
Boston
|
|
Buddhists May Help Biotechies Solve Big Mental Health Woes, Says Merck Vet Ben Shapiro
|
Luke Timmerman |
08/03/09 |
Seattle
|
|
Biogen Idec, Trying to Go Beyond Rituxan, Assembles Cancer Drug Pipeline
|
Luke Timmerman |
07/16/09 |
Boston
|
|
OVP Leads $15M Series C Round for Limerick BioPharma
|
Gregory T. Huang |
07/15/09 |
Seattle
|
|
Aveo Pieces Together a Plan to Rival Big Boys of Cancer Drug World
|
Luke Timmerman |
06/29/09 |
Boston
|
|
Novartis Backing Enlight Biosciences
|
Ryan McBride |
06/15/09 |
Boston
|
|
Trius Looks to Cut a Deal, Gears Up For Final Stage of Trials with New Antibiotic
|
Luke Timmerman |
06/12/09 |
San Diego
|
|
Trius, Developer of Antibiotic for Deadly MRSA Bacteria, Passes Key Test
|
Luke Timmerman |
06/08/09 |
San Diego
|
|
Novocell Snaps Up Second Stem Cell Patent, New CEO Pursues “Next Big Field” of Biotech
|
Luke Timmerman |
06/03/09 |
San Diego
|
|
Concert Pharma Jamming with Glaxo in Deal with $1B-Plus Potential
|
Ryan McBride |
06/02/09 |
Boston
|
|
ASCO Weekend Highlights: ImmunoGen, Antigenics, Aveo Show Off Cancer Drug Findings
|
Luke Timmerman |
06/01/09 |
Boston
|
|
Page 1 of
4 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
